Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197129 | 1.00 | MME (0.42) | MMECA14CA12CA7CA9 | |
| SCHEMBL18993921 | 0.83 | MME (0.40) | MMECA14CA12CA7CA9 | |
| SCHEMBL3015762 | 0.83 | MME (0.40) | MMECA14CA12CA7CA9 | |
| Hydrochloric Acid SCHEMBL30901054 | 0.82 | MME (0.39) | MMECA14CA12CA7CA9 | |
| SCHEMBL26205798 | 0.81 | TSHR (0.36) | MMECHRNB2CHRNA4 | |
| SCHEMBL10367281 | 0.81 | CHRNB2 (0.33) | MMECHRNB2CHRNA4 | |
| SCHEMBL26205780 | 0.81 | TSHR (0.36) | MMECHRNB2CHRNA4 | |
| SCHEMBL196404 | 0.81 | ALDH1A1 (0.37) | CA12CA9SMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL10367282 | 0.81 | CHRNB2 (0.33) | MMECHRNB2CHRNA4 | |
| SCHEMBL196403 | 0.81 | ALDH1A1 (0.37) | CA12CA9SMN1; SMN2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230096494-A1 | Isobaric Multiplex Reagents for Carbonyl Containing Compound High-Throughput Quantitative Analysis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-03-30 | — | — | US | disclosed |
| US-11535576-B2 | Carbonyl containing compound high-throughput quantitative analysis using isobaric multiplex reagents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-20190225559-A1 | Isobaric Multiplex Reagents for Carbonyl Containing Compound High-Throughput Quantitative Analysis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-07-25 | — | — | US | disclosed |
| US-9603943-B2 | Polyesteramide platform for site specific drug delivery | ABBOTT CARDIOVASCULAR SYSTEMS INC. (US) | 2017-03-28 | — | — | US | disclosed |
| WO-2013062947-A1 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-8158330-B2 | Resist protective coating composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8088537-B2 | Resist top coat composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090286182-A1 | RESIST PROTECTIVE COATING COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090197200-A1 | Resist top coat composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535576-B2 | Carbonyl containing compound high-throughput quantitative analysis using isobaric multiplex reagents | MCCC2, FABP4, FABP5 | MME 1038/4885CA14 108/4885CA12 181/4885 |
| US-20230096494-A1 | Isobaric Multiplex Reagents for Carbonyl Containing Compound High-Throughput Quantitative Analysis | FABP4, MCCC2, FABP5 | MME 946/4885CA14 125/4885CA12 186/4885 |
| US-20190225559-A1 | Isobaric Multiplex Reagents for Carbonyl Containing Compound High-Throughput Quantitative Analysis | FABP4, MCCC2, FABP5 | MME 946/4885CA14 125/4885CA12 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.